Parkinson's disease (PD) is a neurodegenerative disorder associated with loss of striatal
dopamine, secondary to degeneration of midbrain dopamine (mDA) neurons in the …

In pursuit of treating Parkinson's disease with cell replacement therapy, differentiated
induced pluripotent stem cells (iPSC) are an ideal source of midbrain dopaminergic (mDA) …

In Parkinson's disease (PD), there are currently no effective therapies to prevent or slow
down disease progression. Cell replacement therapy using human pluripotent stem cell …

Autologous transplantation of patient-specific induced pluripotent stem cell (iPSC)-derived
neurons is a potential clinical approach for treatment of neurological disease. Preclinical …

A cell-based therapy for the replacement of dopaminergic neurons has been a long-term
goal in Parkinson's disease research. Here, we show that autologous engraftment of A9 …

Induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neurons are an expected
source for cell-based therapies for Parkinson's disease (PD). The regulatory criteria for the …

Parkinson's Disease (PD) is an intractable disease resulting in localized neurodegeneration
of dopaminergic neurons of the substantia nigra pars compacta. Many current therapies of …

Parkinson disease (PD) involves the selective loss of midbrain dopamine (mDA) neurons
and is a possible target disease for stem cell–based therapy. Human induced pluripotent …

A major challenge for clinical application of pluripotent stem cell therapy for Parkinson's
disease (PD) is large-scale manufacturing and cryopreservation of neurons that can be …

Cell replacement therapy could be an important treatment strategy for Parkinson's disease
(PD), which is caused by the degeneration of dopamine neurons in the midbrain (mDA). The …